SkinMedica Announces Promotion of Theodore Schwarz to President

CARLSBAD, Calif., Dec. 13, 2010 /PRNewswire/ -- SkinMedica, the fastest-growing professional skin care company in the United States, announced today the promotion of Ted Schwarz to President. Mary Fisher, formerly President and Chief Executive Officer, will continue to lead SkinMedica as Chief Executive Officer.

(Logo: http://photos.prnewswire.com/prnh/20100810/NY48207LOGO )

"Ted has directed sector-leading performance at SkinMedica since his arrival five years ago," commented Mary Fisher, CEO.  "Under his leadership, we have more than doubled our aesthetics skin care revenue, delivering a compounded annual growth rate of more than 35 percent.  In 2010, we implemented his vision for partnering and education and delivered 65 percent year-over-year growth for the physician practices that participated in our targeted educational initiatives.

"His direction, leadership and deep intuition for our business, and the importance of building solid relationships within our physician channels, are invaluable as we introduce new categories of innovative products beyond anti-aging, expand the market and continue to be leaders in the growth of aesthetics."

Mr. Schwarz has dedicated more than 20 years of his career to the specialty of dermatology, in both the medical and aesthetics fields.  He joined SkinMedica in January 2005 as Vice President of Aesthetics Sales and Marketing, and was promoted to Senior Vice President and General Manager in January 2009.  Previously, he served as Vice President of Sales for La Roche-Posay, a division of L'Oreal.  Prior to that, he was the Global Strategic Marketing and Business Development Manager at Galderma International, France, after more than 10 years in managerial and sales positions with the company.

He received his Bachelor of Arts degree in Marketing and Business from Michigan State University.

About SkinMedica, Inc.

SkinMedica, Inc. is focused on developing, acquiring and commercializing products that treat dermatologic conditions and improve the appearance of skin. The Company markets and sells to physicians, with a focus on aesthetics, both prescription and non-prescription skin care products. The Company's full line of aesthetic skin care products includes the revolutionary TNS Essential Serum™ and hallmark TNS Recovery Complex®. The formulations in the Company's clinical skin care collection enhance skin appearance, reduce signs of aging and provide other skin care benefits.

SkinMedica's prescription products include VANIQA® (eflornithine hydrochloride) Cream, 13.9%, the only FDA-approved prescription product for the reduction of unwanted facial hair in women and EpiQuin® Micro Cream (4% hydroquinone) for hyperpigmentation, or "brown spots" that commonly result from aging, inflammation or sun exposure.

SkinMedica is based in Carlsbad, California. For more information, visit: www.skinmedica.com.

TNS Recovery Complex®, VANIQA®, EpiQuin® Micro, and SkinMedica®, are registered trademarks of SkinMedica, Inc and affiliates.

SOURCE SkinMedica, Inc.